The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Emerging Protein Targets for Anticancer Metallodrugs: Inhibition of Thioredoxin Reductase and Cathepsin B by Antitumor Ruthenium(II)−Arene Compounds
Open accessAbstract
A series of ruthenium(II)-arene (RAPTA) compounds were evaluated for their ability to inhibit thioredoxin reductase (either cytosolic or mitochondrial) and cathepsin B, two possible targets for anticancer metallodrugs. In general, inhibition of the thioredoxin reductases was lower than that of cathepsin B, although selected compounds were excellent inhibitors of both classes of enzymes in comparison to other metal-based drugs. Some initial structure-activity relationships could be established. On the basis of the obtained data, different mechanisms of binding/inhibition appear to be operative; remarkably the selectivity of the ruthenium compounds toward solid metastatic tumors also correlates to the observed trends. Notably, docking studies of the interactions of representative RAPTA compounds with cathepsin B were performed that provided realistic structures for the resulting protein-metallodrug adducts. Good agreement was generally found between the inhibiting potency of the RAPTA compounds and the computed stability of the corresponding cat B/RAPTA adducts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mohanam, S., Jasti, S. L., Kondraganti, S. R., Chandrasekar, N., Lakka, S. S., Kin, Y., Fuller, G. N., Yung, A. W. K., Kyritsis, A. P., Dinh, D. H., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204480 · Cited by 87
RetractedPROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Density-functional thermochemistry. III. The role of exact exchange
Becke, A. D. (1993) · The Journal of Chemical Physics · doi:10.1063/1.464913 · Cited by 103,767
Density-functional exchange-energy approximation with correct asymptotic behavior
Becke, A. D. (1988) · Physical Review A · doi:10.1103/physreva.38.3098 · Cited by 53,711
Hay, P. J., & Wadt, W. R. (1985) · The Journal of Chemical Physics · doi:10.1063/1.448975 · Cited by 15,577
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
Improved protein–ligand docking using GOLD
Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., & Taylor, R. D. (2003) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10465 · Cited by 3,067
Physiological functions of thioredoxin and thioredoxin reductase
Arnér, E. S. J., & Holmgren, A. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01701.x · Cited by 2,525
Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation
Jones, G., Willett, P., & Glen, R. C. (1995) · Journal of Molecular Biology · doi:10.1016/s0022-2836(95)80037-9 · Cited by 1,546
Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug
(1999) · Wiley eBooks · doi:10.1002/9783906390420 · Cited by 1,296
Cited by
Organometallic Anticancer Compounds
Gasser, G., Ott, I., & Metzler-Nolte, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm100020w · Cited by 1,624
Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z.-S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,017
Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs
Liu, W., & Gust, R. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35314h · Cited by 762
Focus on mammalian thioredoxin reductases — Important selenoproteins with versatile functions
Arnér, E. S. J. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.01.014 · Cited by 673
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs
Bindoli, A., Rigobello, M. P., Scutari, G., Gabbiani, C., Casini, A., & Messori, L. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.026 · Cited by 595
Self-citationRecent developments in ruthenium anticancer drugs
Levina, A., Mitra, A., & Lay, P. A. (2009) · Metallomics · doi:10.1039/b904071d · Cited by 592
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
Self-citationRu(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
Thota, S., Rodrigues, D. A., Crans, D. C., & Barreiro, E. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01689 · Cited by 476
The development of RAPTA compounds for the treatment of tumors
Murray, B. S., Babak, M. V., Hartinger, C. G., & Dyson, P. J. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2015.06.014 · Cited by 455
Self-citationLazarević, T., Rilak, A., & Bugarčić, Ž. D. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.007 · Cited by 428
Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation
Romero-Canelón, I., & Sadler, P. J. (2013) · Inorganic Chemistry · doi:10.1021/ic400835n · Cited by 396
Designing organometallic compounds for catalysis and therapy
Noffke, A. L., Habtemariam, A., Pizarro, A. M., & Sadler, P. J. (2012) · Chemical Communications · doi:10.1039/c2cc30678f · Cited by 370
Organometallic ruthenium-based antitumor compounds with novel modes of action
Ang, W. H., Casini, A., Sava, G., & Dyson, P. J. (2011) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2010.11.009 · Cited by 366
Self-citationThe ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1
Cheff, D. M., Huang, C., Scholzen, K. C., Gencheva, R., Ronzetti, M. H., Cheng, Q., Hall, M. D., & Arnér, E. S. J. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102703 · Cited by 255
Metadata
- Authors
- Casini, A., Gabbiani, C., Sorrentino, F., Rigobello, M. P., Bindoli, A., Geldbach, T. J., Marrone, A., Re, N., Hartinger, C. G., Dyson, P. J., & Messori, L.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-10-04
- Volume
- 51
- Issue
- 21
- Pages
- 6773-6781
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2045464802
- Cited by
- 270
- References
- 39
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.